Sugi Predict

Sugi Predict / Compounds / SCHEMBL2937246

SCHEMBL2937246

SCHEMBL2937246

O=C(c1cnccc1CN1CC(=O)N(c2ccc(OC(F)(F)F)cc2)C1=O)N1CCCCC1

nearest known ligand 0.38

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ EPHX2 P34913 3/20 0.38
▸ PPARD Q03181 2/20 0.37
▸ PPARA Q07869 2/20 0.37
▸ NAMPT P43490 2/20 0.35
▸ KCNA5 P22460 1/20 0.34
▸ TP53 P04637 5/20 0.34
▸ MDM2 Q00987 5/20 0.34
▸ TEAD1 P28347 1/20 0.34
▸ TEAD4 Q15561 1/20 0.34
▸ TEAD2 Q15562 1/20 0.34
▸ TEAD3 Q99594 1/20 0.34
▸ GAA P10253 1/20 0.33
▸ PPARG P37231 1/20 0.33
▸ NTRK1 P04629 1/20 0.33
▸ HRH3 Q9Y5N1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2938294 0.91 EPHX2 (0.41) EPHX2PPARDPPARANAMPTKCNA5
SCHEMBL2936817 0.91 EPHX2 (0.41) EPHX2PPARDPPARANAMPTKCNA5
SCHEMBL2937317 0.89 KCNA5 (0.43) KCNA5TP53MDM2GAA
SCHEMBL2939834 0.87 PPARD (0.42) EPHX2PPARDPPARANAMPTPPARG
SCHEMBL2992187 0.86 ROCK2 (0.40) PPARDPPARANAMPTPPARGNTRK1
SCHEMBL2937338 0.86 IGF1R (0.38) PPARDPPARATP53NTRK1
SCHEMBL2937997 0.85 LMNA (0.37) PPARDPPARANAMPTGAA
SCHEMBL2938440 0.84 PPARD (0.40) PPARDPPARAPPARGNTRK1
SCHEMBL2939008 0.84 PPARD (0.40) PPARDPPARATEAD1TEAD4TEAD2
SCHEMBL2940517 0.84 PPARD (0.41) PPARDPPARAGAAPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825115-B2 Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-11-02 — — US disclosed
EP-1599464-B1 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2010-09-22 — — EP disclosed
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-08 — — US disclosed
US-7354933-B2 Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate AVENTIS PHARMA SA (FR) 2008-04-08 — — US disclosed
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2004-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors PRKG1, PRKACA, CMPK1 EPHX2 3969/4885PPARD 3189/4885PPARA 4338/4885
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors PRKG1, PRKACA, PRKCA EPHX2 3424/4885PPARD 3572/4885PPARA 4692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.